-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on vTv Therapeutics, Maintains $49 Price Target

Benzinga·03/11/2026 17:25:21
Listen to the news
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $49 price target.